FDA warned Walgreens over three store-brand eye drops sold as unapproved new drugs and tied to contract manufacturer manufacturing violations.
What happened
In August 2023, FDA reviewed www.walgreens.com and found Walgreens Allergy Eye Drops, Stye Eye Drops, and Pink Eye Drops offered for sale with claims to relieve allergy, stye, and pink eye symptoms. FDA determined the products are unapproved new drugs and not generally recognized as safe and effective; no FDA-approved application is in effect. FDA also said the products are made by a contract manufacturer with CGMP (current good manufacturing practice) violations and raised a safety concern about silver sulfate used as an ophthalmic preservative.
What FDA found
The eye drops are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d), 355(a)The products are not generally recognized as safe and effective for their labeled uses, so they are new drugs under the law.
FD&C Act section 201(p), 21 U.S.C. 321(p)Website and labeling claims show the products are intended to treat disease or affect body function, making them drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA says the products are adulterated because the contract manufacturer did not follow CGMP.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); sections 301(a)/(c), 21 U.S.C. 331(a)/(c)FDA raised a safety concern that silver sulfate used as an ophthalmic preservative is inconsistent with the requirement that preservatives be suitable and harmless.
21 C.F.R. 200.50(b)(1)
What FDA wants
FDA asks Walgreens to notify it in writing within 15 working days of the steps taken to correct the violations, with explanations and supporting documents, and to state a completion date if more time is needed.
Who should pay attention
- retailers selling store-brand OTC eye drops
- contract manufacturers of homeopathic ophthalmic products
- brands that rely on contract manufacturers for CGMP compliance
This is a summary. Read the original letter on fda.gov.